Study of ZB001 in Chinese Patients With Thyroid Eye Disease
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human
IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and
pharmacokinetics（PK）/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid
Eye Disease.